Abstracts tagged "Adalimumab"

Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 561 • 2014 ACR/ARHP Annual Meeting
A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis
Sofia Ramiro¹, Maureen C. Turina², Dominique L. Baeten³, Philip J. Mease⁴, Jacqueline E. Paramarta², In-Ho Song⁵, Aileen L. Pangan⁶ and Robert Landewé⁷, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: We assessed the discriminatory aspects of disease activity measures and response criteria between adalimumab (ADA) and placebo (PBO) in 2 studies of patients (pts)…
Abstract Number: 2581 • 2014 ACR/ARHP Annual Meeting
Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint
Xenofon Baraliakos¹, Joachim Sieper², Su Chen³, Aileen L. Pangan³ and Jaclyn K. Anderson³, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) and active disease may have objective evidence of inflammation, either as bone marrow edema (BME) on magnetic…
Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting
Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 558 • 2014 ACR/ARHP Annual Meeting
Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index
Philip J. Mease¹, Denis Poddubnyy², Su Chen³ and Jaclyn K. Anderson³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: C-reactive protein (CRP), an objective measure of active inflammation, has been associated with obesity, with both overweight and obese individuals more likely to have…
Abstract Number: 2510 • 2014 ACR/ARHP Annual Meeting
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: To achieve comprehensive disease control (CDC; defined as simultaneous achievement of DAS28 < 3.2, HAQ-DI < 0.5 and ΔmTSS ≤ 0.5) or comprehensive disease…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…
Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Marie-Pier Payette¹, Jean-Pierre Raynauld¹, Jean-Pierre Pelletier², Louis Bessette³, Edith Villeneuve¹, Boulos Haraoui¹, Isabelle Fortin⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ³Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 500 • 2014 ACR/ARHP Annual Meeting
Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement
Noortje van Herwaarden¹, Chantal Bouman², Aatke van der Maas³, Ronald F. van Vollenhoven⁴, Johannes W.J. Bijlsma⁵, Frank H.J. van den Hoogen⁶, Alfons A. den Broeder¹ and Bart van den Bemt⁷, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁷Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity…
Abstract Number: 2393 • 2014 ACR/ARHP Annual Meeting
Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
Gurjit S. Kaeley¹, Midori Jane Nishio², Daryl MacCarter³, Jenny Griffith⁴, Hartmut Kupper⁵, Vishvas Garg⁶ and Jasmina Kalabic⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose Methotrexate (MTX) is used in monotherapy or in combination with other DMARDs in the treatment of patients (pts) with rheumatoid arthritis (RA). We evaluated…
Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis â€“ an Interim Analysis
Stephen Oakley^1,2,3, Niloofar Esmaili⁴, Gabor Major⁴, David Mathers^4,5, Siva Ratnarajah⁶, John van der Kallen⁵, Mark Collins⁶, Marc Toh⁶ and John Glass⁴, ¹Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, ⁴Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ⁵Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, ⁶Rheumatology, Private Practice, Newcastle, Australia
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…
Abstract Number: 2043 • 2014 ACR/ARHP Annual Meeting
How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists?
Aysa Hacioglu¹, Yesim Ozguler², Sermin Borekci³, Vedat Hamuryudan¹, Hanefi Deniz Kecebas¹, Ethem Koray Tascilar², Melike Melikoglu⁴, Serdal Ugurlu¹, Emire Seyahi¹, Izzet Fresko², Huri Ozdogan¹, Sebahattin Yurdakul¹, Gul Ongen³ and Gulen Hatemi¹, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³University of Istanbul, Cerrahpasa Medical Faculty, Department of Pulmonary Diseases, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: During the development of algorythms for screening latent tuberculosis before starting TNF-alpha antagonists, it is assumed that BCG vaccination causes false positive PPD and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.